Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis
Authors:
- 19 August 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 133 (3) , 454-460
Abstract
SUMMARY: Glatiramer acetate (GA) is effective in the treatment of Multiple Sclerosis (MS) presumably by the induction of an immunoregulatory T-cell response. We have previously shown that GA directly induces the Th2 cytokines IL-13 and IL-5 in T-cells in vitro. In the present study we compared the in vitro response to GA in healthy controls, untreated and GA-treated MS patients and tested whether the induction of IL-13 and IL-5 secretion is also detectable in the serum of 25 MS patients treated with GA. Patients were grouped into clinical responders and nonresponders in order to determine a possible correlation with the immunological response. As a result we found a significant increase of IL-13 in the serum of clinical GA-responders whereas IL-13 was not detectable in controls, untreated MS (P < 0·001) and nonresponders (P = 0·015). Similarly, GA-treatment increased serum levels of IL-5 (P = 0·001). The correlation of serum IL-5 and clinical response was also significant (P = 0·039), however, there was an overlap between the different groups. The selective induction of IL-13 and IL-5 but not IL-4 by GA treatment suggests that the specific biological functions of these cytokines might be important for the therapeutic mechanism of GA. Measurement of serum IL-13 and IL-5 levels is a simple and inexpensive tool for monitoring the response to GA in MS patients.Keywords
This publication has 27 references indexed in Scilit:
- IL-4 Induces Characteristic Th2 Responses Even in the Combined Absence of IL-5, IL-9, and IL-13Immunity, 2002
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetateJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 yearsMultiple Sclerosis Journal, 2000
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.Journal of Experimental Medicine, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluidAnnals of Neurology, 1989
- Selective Loss of the Suppressor-Inducer T-Cell Subset in Progressive Multiple SclerosisNew England Journal of Medicine, 1987
- Immunogenic potentials of copolymer I in normal human lymphocytesNeurology, 1985